Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02493920
Other study ID # MECCANICA SLI
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date March 2016
Est. completion date March 2018

Study information

Verified date February 2021
Source Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lung protection should start in the delivery room where, from the first breaths, the preterm infant can be helped to clear the lung fluid and to recruit alveolar spaces and establish the functional residual capacity (FRC). Sustained lung inflation (SLI) applied at birth in the delivery room has been demonstrated to lead to clearance of lung fluid and achievement of a precocious functional residual capacity (FRC) both in animal and human studies. SLI associated to an adequate positive end expiratory pressure (PEEP) may help the efficacy of the respiratory effort in lung of preterm infants at risk for respiratory distress syndrome (RDS) and reduce need of mechanical ventilation (MV). Further studies are required to evaluate the clinical utility of this maneuver. The ability to monitor what happens to the lungs while applying different recruitment maneuvers in preterm infants would allow the definition of a procedure that allows optimal assistance to improve the FRC. One promising approach is provided by the forced oscillation technique (FOT). During forced oscillations, a small amplitude sinusoidal pressure stimulus is applied to the airway opening and the mechanical response of the respiratory system is studied by means of the total respiratory input impedance (Zin). Zin is a complex number that can be expressed as real part, called resistance (Rrs), and imaginary part, called reactance (Xrs). Particularly, it has been recently shown that Xrs measured at 5 Hz is very sensible to changes in the mechanics of lung periphery and provides accurate information about lung volume recruitment and derecruitment. The main purpose of this work is to apply FOT to the assessment of lung function in newborns submitted to SLI at birth. The investigators hypothesized that the application in the delivery room of the SLI in the preterm infant is effective in achieving a greater FRC and therefore a greater value of Xrs compared to a control group not treated with the SLI.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2018
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender All
Age group 25 Weeks to 36 Weeks
Eligibility Inclusion Criteria: - Gestational age (GA) at least 25 weeks but less than 36 completed weeks by best obstetrical estimate Exclusion Criteria: - Refusal of antenatal informed consent - Known major anomalies, pulmonary hypoplasia - Severe perinatal suffering

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Sustained lung inflation
Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm).
Device:
mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Reactance (Xrs) values measured by the forced oscillation technique (FOT) Baseline and at 5 minutes of life (that is, before and at the end of the SLI)
Secondary Need for intubation within the first 72 hours of life 72 hours of life
Secondary Duration of respiratory support (ventilation, CPAP, supplemental oxygen) During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
Secondary Death in hospital During hospitalization - up to 40 weeks Post Menstrual Age (PMA)
Secondary Number of surfactant doses During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
Secondary Retinopathy of prematurity (ROP) stage 3 or greater requiring treatment 40 weeks Post Menstrual Age (PMA)
Secondary Incidence of Patent Ductus Arteriosus (PDA) requiring treatment During hospitalization - up to 36 weeks Post Menstrual Age (PMA)
Secondary Incidence of Bronchopulmonary dysplasia Defined according to the criteria of Jobe and Bancalari (Jobe A, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9) 36 weeks Post Menstrual Age (PMA)
Secondary Incidence of Intracranial Hemorrhages (ICH) We used the ICH classification of Papile et al During hospitalization- up to 40 weeks Post Menstrual Age (PMA)
Secondary Length of hospital stay Average discharge between 36 - 40 weeks PMA
See also
  Status Clinical Trial Phase
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Completed NCT04908397 - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension Phase 1
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Completed NCT03682354 - ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Completed NCT00281216 - Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations N/A
Terminated NCT00233207 - IC14 Antibodies to Treat Individuals With Acute Lung Injury Phase 2
Completed NCT00269256 - Stress, Environment, and Genetics in Urban Children With Asthma N/A
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Active, not recruiting NCT00115297 - Montelukast for Early Life Wheezing Phase 2/Phase 3
Completed NCT00091767 - Genetic Studies in Difficult to Treat Asthma: TENOR N/A
Completed NCT00094276 - Intervention for Improving Asthma Care for Minority Children in Head Start N/A
Completed NCT00069823 - Study of Acid Reflux in Asthma Phase 3
Completed NCT00233168 - Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents N/A
Completed NCT00083798 - Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland N/A